Comparative Analysis: MK 677 and MK 2866

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

Introduction

MK 677 and MK 2866 are commonly grouped within the category of selective androgen receptor modulators (SARMs). However, MK 677 does not strictly qualify as a SARM. Both compounds are widely studied for their ability to promote skeletal muscle growth and repair, while minimizing the adverse effects typically associated with traditional anabolic therapies. MK 2866, also known as ostarine, has been investigated for conditions that impair muscle and bone health. MK 677, also referred to as ibutamoren, has been explored for growth hormone deficiency and muscle wasting syndromes. Although they share similarities, their pharmacological actions and clinical implications differ substantially.

Molecular Characteristics

MK 677 (Ibutamoren)

• Formula: C27H36N4O5S
• Molecular Weight: 528.7 g/mol
• PubChem CID: 9939050
• CAS Number: 159634-47-6
• Synonyms: Ibutamoren, L-163,191

MK 2866 (Ostarine)

• Formula: C19H14F3N3O3
• Molecular Weight: 389.3 g/mol
• PubChem CID: 11326715
• CAS Number: 841205-47-8
• Synonyms: Ostarine, Enobosarm

Mechanistic Pathways

Selective Androgen Receptor Modulators (SARMs)
SARMs act on androgen receptors, influencing muscle growth, bone density, fat metabolism, and tissue repair. They are considered more selective and generally produce fewer systemic side effects than traditional anabolic agents.

MK 677
Unlike SARMs, MK 677 functions as a non-peptide agonist of the growth hormone secretagogue receptor (ghrelin receptor). It elevates circulating growth hormone (GH) and insulin-like growth factor 1 (IGF-1) without binding directly to androgen receptors. Importantly, this mechanism prevents suppression of endogenous testosterone levels, thereby reducing the likelihood of androgen-related side effects.

MK 2866
MK 2866 binds directly to the androgen receptor, exerting anabolic effects similar to testosterone. This mechanism enhances muscle synthesis, inhibits muscle breakdown, and may reduce myostatin expression. However, receptor binding can also suppress natural androgen production, necessitating treatment cycles to mitigate adverse endocrine effects.

Effects on Skeletal Muscle

MK 677
Clinical investigations have shown that MK 677 increases GH and IGF-1 levels, improving lean body mass and reducing LDL cholesterol in older populations. In younger individuals, its effects on muscle mass are more pronounced when combined with resistance training. Additionally, it supports nitrogen retention, an important factor in mitigating muscle catabolism, particularly in critical care settings.

MK 2866
Research demonstrates that MK 2866 stimulates muscle hypertrophy and prevents atrophy via androgen receptor activation. Preclinical studies suggest it enhances muscle vascularization and increases IGF-1 expression. While its direct anabolic potential may exceed that of MK 677, comprehensive human data remain limited.

Cardiovascular Considerations

MK 677
By increasing nitric oxide production and stimulating endothelial progenitor cell activity, MK 677 may enhance vascular health. Current findings suggest a net positive effect on cardiovascular outcomes.

MK 2866
Evidence indicates that MK 2866 can reduce HDL cholesterol levels, which may raise concern for cardiovascular risk. Conversely, it lowers triglycerides and total cholesterol while preserving cardiac muscle mass. The long-term cardiovascular implications remain unclear and require further research.

Implications for Bone Health

MK 677
Studies indicate a shift toward bone formation, supported by increases in serum osteocalcin and bone-specific alkaline phosphatase. Clinical trials in older adults with hip fractures have demonstrated improvements in gait speed and reductions in fall frequency.

MK 2866
MK 2866 also promotes bone deposition through androgen receptor stimulation. However, improvements in bone strength and mechanical integrity have not yet been conclusively demonstrated. Longer studies are needed to determine its full impact on skeletal resilience.

Influence on Sleep Regulation

MK 677
Administration of MK 677 has been associated with improved sleep architecture. Research shows increases in slow-wave (stage 4) sleep by approximately 50 percent and significant improvements in REM sleep parameters. These benefits suggest potential applications in sleep-related disorders and cognitive preservation.

MK 2866
Currently, MK 2866 has not demonstrated effects on sleep quality. However, androgen deprivation is linked to sleep disturbances, which raises the possibility that androgen receptor modulation may indirectly influence sleep health.

Summary

Both MK 677 and MK 2866 offer therapeutic promise in addressing muscle and bone wasting conditions, with notable distinctions in mechanism and clinical impact. MK 677 primarily enhances growth hormone and IGF-1 pathways, providing additional benefits in bone metabolism and sleep regulation without suppressing testosterone. MK 2866, by directly targeting androgen receptors, demonstrates stronger anabolic potential but carries risks of androgen suppression and possible lipid alterations.

At present, the body of evidence supporting MK 677 is more extensive, particularly regarding bone health and sleep physiology. MK 2866 remains under active investigation, with growing clinical interest in its potential applications. Both compounds warrant continued research to define optimal use, long-term safety, and therapeutic integration.

REFERENCES

1. Copinschi, G., Leproult, R., Van Onderbergen, A., Caufriez, A., Cole, K. Y., Schilling, L. M., Mendel, C. M., De Lepeleire, I., Bolognese, J. A., & Van Cauter, E. (1997). Prolonged oral treatment with MK-677, a novel growth hormone secretagogue, improves sleep quality in man. Neuroendocrinology, 66(4), 278–286. https://doi.org/10.1159/000127249
2. Murphy, M. G., Plunkett, L. M., Gertz, B. J., He, W., Wittreich, J., Polvino, W. M., & Clemmons, D. R. (1998). MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. The Journal of clinical endocrinology and metabolism, 83(2), 320–325. https://doi.org/10.1210/jcem.83.2.4551
3. Lambert C. P. (2021). Should the FDA’s criteria for the clinical efficacy of cachexia drugs be changed? Is Ostarine safe and effective?. Journal of cachexia, sarcopenia and muscle, 12(3), 531–532. https://doi.org/10.1002/jcsm.12695
4. Roch, P. J., Henkies, D., Carstens, J. C., Krischek, C., Lehmann, W., Komrakova, M., & Sehmisch, S. (2020). Ostarine and Ligandrol Improve Muscle Tissue in an Ovariectomized Rat Model. Frontiers in endocrinology, 11, 556581. https://doi.org/10.3389/fendo.2020.556581
5. National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 11326715, Enobosarm. Retrieved September 13, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/Enobosarm.
6. National Center for Biotechnology Information (2025). PubChem Compound Summary for CID 9939050, 1-(Methanesulfonyl)-1′-(2-methylalanyl-O-benzylseryl)-1,2-dihydrospiro(indole-3,4′-piperidine). Retrieved September 13, 2025 from https://pubchem.ncbi.nlm.nih.gov/compound/9939050.

Sigalos, J. T., & Pastuszak, A. W. (2018). The Safety and Efficacy of Growth Hormone Secretagogues. Sexual medicine reviews, 6(1), 45–53. https://doi.org/10.1016/j.sxmr.2017.02.004